Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy

References

• Strohl MP, Raigani S, Ammori JB, et al. Surgery for localized pancreatic cancer: the trend is not improving. Pancreas. 2016;45(5):687–693.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18(5):543–548.
   PubMed Web of Science ®Google Scholar
• Sadot E, Doussot A, O’Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512–3521.
   PubMed Web of Science ®Google Scholar
• Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137.
   PubMed Web of Science ®Google Scholar
• Zhong J, Patel K, Switchenko J, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123(18):3486–3493.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313–322.
   PubMed Web of Science ®Google Scholar
• Katz MHG, Ou FS, Herman JM, for the Alliance for Clinical Trials on Oncology, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17(1):505.
   PubMed Web of Science ®Google Scholar
• Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–522.
   PubMed Web of Science ®Google Scholar
• Rudra S, Jiang N, Rosenberg SA, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8(5):2123–2132.
   PubMed Web of Science ®Google Scholar
• Liu F, Erickson B, Peng C, et al. Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(3):e423–9.
   PubMed Web of Science ®Google Scholar
• Loi M, Magallon-Baro A, Suker M, et al. Pancreatic cancer treated with SBRT: effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol. 2019; 134:67–73.
   PubMed Web of Science ®Google Scholar
• El-Bared N, Portelance L, Spieler BO, et al. Dosimetric benefits and practical pitfalls of daily online adaptive mri-guided stereotactic radiation therapy for pancreatic cancer. Pract Radiat Oncol. 2019;9(1):e46–e54.
   PubMed Web of Science ®Google Scholar
• Papalazarou C, Klop GJ, Milder MTW, et al. CyberKnife with integrated CT-on-rails: System description and first clinical application for pancreas SBRT. Med Phys. 2017; 44(9):4816–4827.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35.
   PubMed Web of Science ®Google Scholar
• Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):e143–9.
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76(3):S101–S7.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):369–375.
   PubMed Web of Science ®Google Scholar
• Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72(3):678–686.
   PubMed Web of Science ®Google Scholar
• Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–1137.
   PubMed Web of Science ®Google Scholar
• Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979–985.
   PubMed Web of Science ®Google Scholar
• Li Y, Hoisak JD, Li N, et al. Dosimetric benefit of adaptive re-planning in pancreatic cancer stereotactic body radiotherapy. Med Dosim. 2015;40(4):318–324.
   PubMed Web of Science ®Google Scholar
• Magallon-Baro A, Loi M, Milder M, et al. Modeling daily changes in organ-at-risk anatomy in a cohort of pancreatic cancer patients. Radiother Oncol. 2019;134:127–134.
   PubMed Web of Science ®Google Scholar
• Bruynzeel AME, Lagerwaard FJ. The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol. 2019;18:128–130.
   PubMed Web of Science ®Google Scholar